COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
Mult Scler Relat Disord
; 53: 103049, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1253407
ABSTRACT
We report COVID-19 presentation, course and outcomes in teriflunomide-treated MS patients in Argentina. METHODS:
descriptive, retrospective, multicentre, study that included MS patients receiving teriflunomide who developed COVID-19, with clinical follow-up at reference MS centres, also listed in a nationwide registry.RESULTS:
Eighteen MS patients on teriflunomide treatment, from eight MS centres developed COVID-19. The mean age was 41,2 years and 72% of them were female; 94% had diagnosis of relapsing-remitting MS and 6% presented a radiologically isolated syndrome. Median EDSS was 2 (range 0-5.5). The average time on teriflunomide therapy was 3 years. COVID-19 diagnosis was confirmed with nasal swab in 61%. None required hospitalization and they completely recovered from the acute-phase within 7-14 days. All the patients continued their teriflunomide therapy during COVID-19 course. No MS relapses occurred during or after COVID-19 course.CONCLUSION:
Our report adds to the evidence that COVID-19 is mild in patients receiving teriflunomide therapy and that continuing with teriflunomide therapy during Sars-CoV-2 infection is safe and advisable for MS patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
COVID-19
/
Multiple Sclerosis
Type of study:
Cohort study
/
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
Country/Region as subject:
South America
/
Argentina
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS